Evidence map›Paper›PMID 31888639›Full record

ArticleBMC medical genomics2019

Genome analysis and knowledge-driven variant interpretation with TGex.

Dvir Dahary, Yaron Golan, Yaron Mazor, Ofer Zelig, Ruth Barshir, Michal Twik, Tsippi Iny Stein, Guy Rosner, Revital Kariv, Fei Chen and 5 more

Abstract read
In one paragraph

Article in BMC medical genomics, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 33 papers.

0numbers the graph read from it
0cells of the map it votes in
33citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

33 citing papers in PubMed.

  1. Reconsidering a silent variant: SGCA's role in atypical cardiomyopathy.European journal of human genetics : EJHG · 2026
    Article
  2. Article
  3. Article
  4. Article
  5. Novel loss-of-functionFrontiers in endocrinology · 2026
    Article
  6. Multitarget mechanisms of the herb pairFrontiers in pharmacology · 2026
    Article
  7. Review
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Review
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors.

Dvir DaharyClinical Genetics, LifeMap Sciences Inc., Marshfield, MA, 02050, USA. dvird@lifemapsc.com.
Yaron GolanClinical Genetics, LifeMap Sciences Inc., Marshfield, MA, 02050, USA.
Yaron MazorClinical Genetics, LifeMap Sciences Inc., Marshfield, MA, 02050, USA.
Ofer ZeligClinical Genetics, LifeMap Sciences Inc., Marshfield, MA, 02050, USA.
Ruth BarshirDepartment of Molecular Genetics, Weizmann Institute of Science, Rehovot, Israel.
Michal TwikDepartment of Molecular Genetics, Weizmann Institute of Science, Rehovot, Israel.
Tsippi Iny SteinDepartment of Molecular Genetics, Weizmann Institute of Science, Rehovot, Israel.
Guy RosnerDepartment of Gastroenterology, Tel-Aviv Sourasky Medical Center, Tel-Aviv, Israel.
Revital KarivDepartment of Gastroenterology, Tel-Aviv Sourasky Medical Center, Tel-Aviv, Israel.
Fei ChenGenetic and Metabolic Central Laboratory, Birth Defect Prevention Research Institute, Maternal and Child Health Hospital, Children's Hospital of Guangxi Zhuang Autonomous Region, Nanning, 530002, China.
Qiang ZhangGenetic and Metabolic Central Laboratory, Birth Defect Prevention Research Institute, Maternal and Child Health Hospital, Children's Hospital of Guangxi Zhuang Autonomous Region, Nanning, 530002, China.
Yiping ShenGenetic and Metabolic Central Laboratory, Birth Defect Prevention Research Institute, Maternal and Child Health Hospital, Children's Hospital of Guangxi Zhuang Autonomous Region, Nanning, 530002, China.
Marilyn SafranDepartment of Molecular Genetics, Weizmann Institute of Science, Rehovot, Israel.
Doron LancetDepartment of Molecular Genetics, Weizmann Institute of Science, Rehovot, Israel. doron.lancet@weizmann.ac.il.
Simon FishilevichDepartment of Molecular Genetics, Weizmann Institute of Science, Rehovot, Israel. simon.fishilevich@weizmann.ac.il.ORCID 0000-0003-1167-1638

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundThe clinical genetics revolution ushers in great opportunities, accompanied by significant challenges. The fundamental mission in clinical genetics is to analyze genomes, and to identify the most relevant genetic variations underlying a patient's phenotypes and symptoms. The adoption of Whole Genome Sequencing requires novel capacities for interpretation of non-coding variants.

resultsWe present TGex, the Translational Genomics expert, a novel genome variation analysis and interpretation platform, with remarkable exome analysis capacities and a pioneering approach of non-coding variants interpretation. TGex's main strength is combining state-of-the-art variant filtering with knowledge-driven analysis made possible by VarElect, our highly effective gene-phenotype interpretation tool. VarElect leverages the widely used GeneCards knowledgebase, which integrates information from > 150 automatically-mined data sources. Access to such a comprehensive data compendium also facilitates TGex's broad variant annotation, supporting evidence exploration, and decision making. TGex has an interactive, user-friendly, and easy adaptive interface, ACMG compliance, and an automated reporting system. Beyond comprehensive whole exome sequence capabilities, TGex encompasses innovative non-coding variants interpretation, towards the goal of maximal exploitation of whole genome sequence analyses in the clinical genetics practice. This is enabled by GeneCards' recently developed GeneHancer, a novel integrative and fully annotated database of human enhancers and promoters. Examining use-cases from a variety of TGex users world-wide, we demonstrate its high diagnostic yields (42% for single exome and 50% for trios in 1500 rare genetic disease cases) and critical actionable genetic findings. The platform's support for integration with EHR and LIMS through dedicated APIs facilitates automated retrieval of patient data for TGex's customizable reporting engine, establishing a rapid and cost-effective workflow for an entire range of clinical genetic testing, including rare disorders, cancer predisposition, tumor biopsies and health screening.

conclusionsTGex is an innovative tool for the annotation, analysis and prioritization of coding and non-coding genomic variants. It provides access to an extensive knowledgebase of genomic annotations, with intuitive and flexible configuration options, allows quick adaptation, and addresses various workflow requirements. It thus simplifies and accelerates variant interpretation in clinical genetics workflows, with remarkable diagnostic yield, as exemplified in the described use cases. TGex is available at http://tgex.genecards.org/.

Indexed as

Genetic VariationDatabases, GeneticGene FrequencyGenomicsGenotypeHumansMolecular Sequence AnnotationPhenotypeSoftwareUser-Computer InterfaceWorkflowBiomedical knowledgebaseClinical variant interpretation and classificationExome sequencingHamartomatous polyposisNext generation sequencing analysisNon-coding variantsRare genetic diseasesWhole genome sequencing

Identifiers

PMID31888639
PMCPMC6937949

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.